Re:Complete protection by single dose skin patch delivered S...
by pepperberg on Friday June 04, 2021 @05:10AM
(#27391905)
You’re right, they completely differ from each other (regarding their relevance) and should therefore face an adjusted amount of scrutiny.
If you’re one of the top pharmaceutical companies in the world, some press releases and study protocols are simply not enough [1] and should be (imo) discarded.
If you’re a new player (Vaxxas) claiming “complete protection” by testing your product on mice, it’s simply not enough and should be (imo) discarded.
[1] https://blogs.bmj.com/bmj/2020/11/26/peter-doshi-pfizer-and-...
This shows results for ~ 48 transgenic mice. I would say that, at the time, the vaccine reported in the press release from Pfizer had a 99% chance of being approved by FDA, while this vaccine has maybe a 10% chance of being approved by the FDA at best.